Sanofi secures FDA approval for additional flu vaccine manufacturing plant
Commercialisation activities for the US market are already underway for Fluzone High-Dose Quadrivalent
Sanofi's vaccines business, Sanofi Pasteur, has received the go-ahead from the US Food and Drug Administration's Center for Biologics Evaluation and Research for its new $425 million manufacturing facility in Swiftwater, PA.
With the approval, Sanofi has already started production of its Fluzone High-Dose Quadrivalent vaccine — a vaccine designed to offer people 65 years of age and older, protection against four flu viruses — ahead of the 2021–2022 influenza season in the US.
The company's Head of North America Operations, Elain O'Hara, said there is a "fast-growing demand" for the vaccine, given the ten years of data supporting its protection from flu.
According to prescribing information, Fluzone High-Dose Quadrivalent is the only FDA-approved vaccine for superior flu protection in adults 65 years of age and older compared with a standard-dose flu vaccine.
In a statement, the company says it plans to "support other countries in the near future", a sentiment echoed by O'Hara who said the company's combined capacity will produce enough high-dose vaccine for "all people 65 and older in as many countries as possible this flu season and beyond".
The expanded facility will also create up to 200 additional manufacturing jobs.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance